Brief: Nexalin Technology Plans To Present GEN-2 And GEN-3 To FDA For Treatment Of Anxiety And Insomnia

Nexalin Technology

05/01/2023 15:15

Jan 5 (Reuters) - Nexalin Technology Inc  NXL.O :
    * NEXALIN TECHNOLOGY INC - PLANNING TO PRESENT GEN-2 AND
GEN-3 TO
FDA IN Q1 2023 FOR TREATMENT OF ANXIETY AND INSOMNIA
    * NEXALIN TECHNOLOGY INC - STRATEGIC PLANNING FOR A PMA WITH
FDA
FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IS PLANNED FOR
Q3 2023
    * NEXALIN TECHNOLOGY INC - STRATEGIC PLANNING FOR A PMA WILL
BE
SUPPORTED BY A LARGE BLINDED CLINICAL TRIAL WITH GEN-3 HEADSET

Source text for Eikon:  ID:nGNX7fJ708 
Further company coverage:  NXL.O 
 ((Reuters.Briefs@thomsonreuters.com;))